The EVs derived from B16-F10 WT were shown to decrease the proportion of proliferating PD-1-CD8+ T-cells in the spleen and lymph nodes, suggesting that EV-PD-L1 suppresses systemic anti-tumor immunity. The gene discussed is CD8A; the disease is neoplasm.